Amorphous calcium phosphate nanoparticles could function as a novel cancer therapeutic agent by employing a suitable

Milad Pourbaghi-Masouleh, Vahid Hosseini1

  • 1Department of Health Science and Technology, Laboratory of Applied Mechanobiology, ETH, Zürich 8093, Switzerland. vahid.hosseini@hest.ethz.ch.

Insights

Amorphous calcium phosphate nanoparticles (ACPNs) can induce cancer cell apoptosis. Encapsulating ACPNs in liposomes with targeting ligands and cell-penetrating peptides enhances their delivery and efficacy for targeted cancer therapy.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cancer Research

Background:

  • Targeted cancer therapy faces challenges with loading efficacy and controlled release of apoptogenic agents.
  • Developing novel nanocarriers that are inherently apoptogenic simplifies drug delivery.
  • Amorphous calcium phosphate nanoparticle (ACPN) is proposed as a potential apoptogenic agent.

Purpose of the Study:

  • To investigate the potential of amorphous calcium phosphate nanoparticle (ACPN) as a carrier for inducing apoptosis in cancer cells.
  • To enhance ACPN delivery and efficacy through encapsulation in liposomes decorated with targeting ligands (TL) and cell-penetrating peptides (CPP).

Main Methods:

  • Designing a nanovehicular system with ACPN as the core agent.
  • Encapsulating ACPN within a liposome shell to facilitate cytosolic delivery and evade endocytosis.
  • Decorating the liposome surface with Folate as a targeting ligand for cancer cells.
  • Utilizing the trans-activator of transcription (TAT) as a cell-penetrating peptide (CPP) to enhance endosomal escape.

Main Results:

  • ACPNs have the potential to induce apoptosis by elevating cytosolic calcium ion concentration ([Ca2+]c).
  • Liposomal encapsulation and surface modification with TAT and Folate are crucial for effective delivery and targeting.
  • This approach aims to overcome limitations of current nanocarrier systems in cancer therapy.

Conclusions:

  • The proposed nanovehicular system offers a novel strategy for targeted cancer therapy.
  • This approach may lead to a new generation of chemotherapeutic agents with potentially fewer side effects.
  • Further research is warranted to validate the efficacy and safety of this ACPN-based system.

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
167
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.5K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167